Damora Therapeutics (DMRA) Stock Price & Analysis

DMRA$21.60-0.45 -2.04%
BiotechnologyGrowth Stock
Compare
Market cap$1.34BEnterprise value$988.58MRevenue (TTM)$0Market position—

Score

70
Bullish
Value
58
Quality
52
Growth
100

AI Analysis

Snapshot

Damora Therapeutics is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 70/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~143% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

58
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

52
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Damora Therapeutics, Inc. (DMRA) last printed $21.60. Equity value is $1.34B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

20182019202020212022202320242025
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00

About

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Damora Therapeutics (DMRA) Stock Price & Analysis

DMRA price $21.60 -0.45 -2.04%

Ticker
DMRA
Price
$21.60
Change
-0.45 -2.04%
Market cap
$1.34B
Dividend yield
0.00%
Beta
1.51
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
70
Value
58
Quality
52
Growth
100

Stocklytics score rationale: value 58, quality 52, growth 100.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener